Syros Pharmaceuticals Statistics Share Statistics Syros Pharmaceuticals has 26.83M
shares outstanding. The number of shares has increased by 0.39%
in one year.
Shares Outstanding 26.83M Shares Change (YoY) 0.39% Shares Change (QoQ) 0% Owned by Institutions (%) 13.29% Shares Floating 26.68M Failed to Deliver (FTD) Shares 1,823 FTD / Avg. Volume 0.01%
Short Selling Information The latest short interest is 129.16K, so 0.48% of the outstanding
shares have been sold short.
Short Interest 129.16K Short % of Shares Out 0.48% Short % of Float 0.52% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -1.34 and the forward
PE ratio is -0.04.
Syros Pharmaceuticals's PEG ratio is
-0.03.
PE Ratio -1.34 Forward PE -0.04 PS Ratio 22.21 Forward PS 0.4 PB Ratio 13.24 P/FCF Ratio -2.01 PEG Ratio -0.03
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Syros Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 3.95,
with a Debt / Equity ratio of 3.73.
Current Ratio 3.95 Quick Ratio 3.95 Debt / Equity 3.73 Debt / EBITDA -0.39 Debt / FCF -0.56 Interest Coverage -25.16
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $146.12K Profits Per Employee $-2.42M Employee Count 68 Asset Turnover 0.06 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -99.42% in the
last 52 weeks. The beta is 1.56, so Syros Pharmaceuticals's
price volatility has been higher than the market average.
Beta 1.56 52-Week Price Change -99.42% 50-Day Moving Average 0.03 200-Day Moving Average 0.69 Relative Strength Index (RSI) 41.52 Average Volume (20 Days) 20,465,601
Income Statement In the last 12 months, Syros Pharmaceuticals had revenue of 9.94M
and earned -164.57M
in profits. Earnings per share was -5.81.
Revenue 9.94M Gross Profit 7.68M Operating Income -128.99M Net Income -164.57M EBITDA -157.19M EBIT -159.45M Earnings Per Share (EPS) -5.81
Full Income Statement Balance Sheet The company has 139.53M in cash and 62.08M in
debt, giving a net cash position of 77.45M.
Cash & Cash Equivalents 139.53M Total Debt 62.08M Net Cash 77.45M Retained Earnings -722.81M Total Assets 85M Working Capital 35.54M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -109.71M
and capital expenditures -272K, giving a free cash flow of -109.98M.
Operating Cash Flow -109.71M Capital Expenditures -272K Free Cash Flow -109.98M FCF Per Share -3.88
Full Cash Flow Statement Margins Gross margin is 77.33%, with operating and profit margins of -1298.19% and -1656.34%.
Gross Margin 77.33% Operating Margin -1298.19% Pretax Margin -1656.34% Profit Margin -1656.34% EBITDA Margin -1582.08% EBIT Margin -1298.19% FCF Margin -1106.87%
Dividends & Yields SYRS does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for SYRS is $3,
which is 9900% higher than the current price. The consensus rating is "Hold".
Price Target $3 Price Target Difference 9900% Analyst Consensus Hold Analyst Count 5
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Sep 19, 2022. It was a
backward
split with a ratio of 1:10.
Last Split Date Sep 19, 2022 Split Type backward Split Ratio 1:10
Scores Altman Z-Score -15.54 Piotroski F-Score 0
